SPRUCE BIOSCIENCES, INC. SPRB Financial Statement Data


2025 Q2

Submissions

Field Row 1 Row 2
adsh 0000950170-25-064463 0000950170-25-053945
cik 1683553 1683553
name SPRUCE BIOSCIENCES, INC. SPRUCE BIOSCIENCES, INC.
sic 2834 2834
countryba US US
stprba CA CA
cityba SOUTH SAN FRANCISCO SOUTH SAN FRANCISCO
zipba 94080 94080
bas1 611 GATEWAY BOULEVARD, SUITE 740 611 GATEWAY BOULEVARD, SUITE 740
bas2
baph (415) 655-4168 (415) 655-4168
countryma US US
stprma CA CA
cityma SOUTH SAN FRANCISCO SOUTH SAN FRANCISCO
zipma 94080 94080
mas1 611 GATEWAY BOULEVARD, SUITE 740 611 GATEWAY BOULEVARD, SUITE 740
mas2
countryinc US US
stprinc DE DE
ein 812154263 812154263
former
changed
afs 4-NON 4-NON
wksi 0 0
fye 1231 1231
form 10-Q 10-K
period 20250331 20241231
fy 2025 2024
fp Q1 FY
filed 20250506 20250415
accepted 2025-05-06 16:10:00.0 2025-04-15 07:15:00.0
prevrpt 0 0
detail 1 1
instance sprb-20250331_htm.xml sprb-20241231_htm.xml
nciks 1 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0000950170-25-053945 20231231 Accrued Expenses And Other Current Liabilities 14600000.0000 USD 0 0000950170-25-053945
0000950170-25-053945 20231231 Assets 103946000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Common Stock Shares Authorized 200000000.0000 shares 0 us-gaap/2024
0000950170-25-053945 20241231 Common Stock Shares Authorized 200000000.0000 shares 0 us-gaap/2024
0000950170-25-053945 20231231 Common Stock Shares Issued 41029832.0000 shares 0 us-gaap/2024
0000950170-25-053945 20231231 Common Stock Shares Outstanding 41029832.0000 shares 0 us-gaap/2024
0000950170-25-053945 20241231 Deferred Offering Costs Included In Accrued Expenses 0.0000 USD 4 0000950170-25-053945
0000950170-25-053945 20231231 Exercise Of Pre Funded Warrants 8000.0000 USD 4 0000950170-25-053945 Equity Components= Additional Paid In Capital;
0000950170-25-053945 20231231 General And Administrative Expense 12650000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Increase Decrease In Other Operating Assets -96000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Interest Paid Net 225000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Liabilities 27437000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Net Cash Provided By Used In Operating Activities -55964000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Net Income Loss -53036000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-053945 20231231 Other Assets Current 1968000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Other Liabilities Noncurrent 282000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Payments Related To Tax Withholding For Share Based Compensation 311000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Payments To Acquire Investments 0.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Payments To Acquire Property Plant And Equipment 7000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Preferred Stock Value 0.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Preferred Stock Value 0.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Proceeds From Sale Maturity And Collections Of Investments 67665000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Proceeds From Stock Options Exercised 1000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Profit Loss -53036000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20161231 Research And Development Expense 800000.0000 USD 4 us-gaap/2024 Counterparty Name= Eli Lilly And Company; Type Of Arrangement= Lilly License Agreement;
0000950170-25-053945 20231231 Revenues 10089000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Revenues 4911000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20221231 Stockholders Equity -558000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000950170-25-053945 20231231 Stockholders Equity 76509000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Stockholders Equity 4000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-053945 20231231 Stockholders Equity -197232000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-053945 20241231 Stockholders Equity 279085000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-053945 20241231 Stockholders Equity 4000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-053945 20241231 Stock Issued During Period Shares Stock Options Exercised 120328.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-053945 20231231 Accounts Payable Current 3332000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20241231 Liabilities And Stockholders Equity 45209000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 25650000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect -15185000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0000950170-25-064463 20241231 Common Stock Shares Authorized 200000000.0000 shares 0 us-gaap/2024
0000950170-25-064463 20241231 Common Stock Shares Issued 42231285.0000 shares 0 us-gaap/2024
0000950170-25-064463 20241231 Long Term Debt Noncurrent 124000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Long Term Debt Noncurrent 0.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Net Cash Provided By Used In Operating Activities -12727000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Non Cash Lease Expense 65000.0000 USD 1 0000950170-25-064463
0000950170-25-064463 20250331 Proceeds From Stock Options Exercised 0.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Repayments Of Long Term Debt 405000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20161231 Research And Development Expense 800000.0000 USD 4 us-gaap/2024 Counterparty Name= Eli Lilly And Company; Type Of Arrangement= Lilly License Agreement;
0000950170-25-064463 20240331 Restricted Stock Shares Issued Net Of Shares For Tax Withholdings 4639.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-064463 20240331 Share Based Compensation 1562000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20231231 Stockholders Equity 76509000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20231231 Stockholders Equity -197232000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-064463 20240331 Stockholders Equity 4000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-064463 20241231 Stockholders Equity 279085000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-064463 20250331 Stockholders Equity 279629000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-064463 20240331 Stock Issued During Period Shares Stock Options Exercised 120328.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-064463 20250331 Weighted Average Number Of Shares Outstanding Basic 43944946.0000 shares 1 us-gaap/2024
0000950170-25-053945 20241231 Additional Paid In Capital Common Stock 279085000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Assets Current 44206000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20221231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 24732000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 96374000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Deferred Revenue Current 0.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 General And Administrative Expense 14644000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Increase Decrease In Accounts Payable 1906000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Increase Decrease In Deferred Revenue -4911000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Increase Decrease In Other Operating Assets -494000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Interest Expense 307000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Interest Paid Net 369000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Liabilities And Stockholders Equity 45209000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Net Cash Provided By Used In Financing Activities 49140000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Other Assets Current 2276000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 558000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000950170-25-053945 20231231 Payments Of Stock Issuance Costs 2721000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0000950170-25-053945 20231231 Repayments Of Long Term Debt 1622000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Restricted Stock Value Shares Issued Net Of Tax Withholdings -246000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Restricted Stock Value Shares Issued Net Of Tax Withholdings -246000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-053945 20241231 Share Based Compensation 5348000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Stock Issued During Period Shares Employee Stock Purchase Plans 158569.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-053945 20231231 Stock Issued During Period Shares Of Common Stock And Warrants 16116000.0000 shares 4 0000950170-25-053945 Equity Components= Common Stock;
0000950170-25-053945 20241231 Stock Issued During Period Shares Stock Options Exercised 120328.0000 shares 4 us-gaap/2024 Plan Name= Two Thousand And Twenty Equity Incentive Plan;
0000950170-25-053945 20231231 Stock Issued During Period Value Employee Stock Purchase Plan 169000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Stock Issued During Period Value Employee Stock Purchase Plan 66000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-053945 20231231 Stock Issued During Period Value Of Common Stock And Warrants 50895000.0000 USD 4 0000950170-25-053945
0000950170-25-053945 20231231 Stock Issued During Period Value Of Common Stock And Warrants 1000.0000 USD 4 0000950170-25-053945 Equity Components= Common Stock;
0000950170-25-053945 20241231 Accounts Payable Current 1295000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Additional Paid In Capital Common Stock 273737000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Assets 45209000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Cash And Cash Equivalents At Carrying Value 38753000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect 71642000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Commitments And Contingencies USD 0 us-gaap/2024
0000950170-25-053945 20241231 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Common Stock Value 4000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Increase Decrease In Prepaid Deferred Expense And Other Assets -391000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Long Term Debt Noncurrent 1717000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Net Income Loss -47919000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-053945 20231231 Non Cash Lease Expense 230000.0000 USD 4 0000950170-25-053945
0000950170-25-053945 20241231 Operating Expenses 61062000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Operating Lease Liability Noncurrent 1019000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0000950170-25-053945 20241231 Prepaid Expense Current 3177000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20250131 Research And Development Expense 5000000.0000 USD 0 us-gaap/2024 Counterparty Name= H B M Alpha Therapeutics Inc; Subsequent Event Type= Subsequent Event; Type Of Arrangement= H B M License Agreement;
0000950170-25-053945 20231231 Restricted Stock Shares Issued Net Of Shares For Tax Withholdings 349983.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-053945 20231231 Restricted Stock Value Shares Issued Net Of Tax Withholdings -311000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Restricted Stock Value Shares Issued Net Of Tax Withholdings -311000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-053945 20231231 Retained Earnings Accumulated Deficit -197232000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Right Of Use Asset Obtained In Exchange For Operating Lease Liability 0.0000 USD 4 us-gaap/2024
0000950170-25-053945 20221231 Stockholders Equity 3000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-053945 20231231 Stockholders Equity 273737000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-053945 20241231 Weighted Average Number Of Shares Outstanding Basic 41264948.0000 shares 4 us-gaap/2024
0000950170-25-053945 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect -57586000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Depreciation And Amortization 70000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Earnings Per Share Basic -1.2400 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Increase Decrease In Accrued Liabilities 6255000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Increase Decrease In Prepaid Deferred Expense And Other Assets 2636000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Lease Right Of Use Asset 1181000.0000 USD 0 0000950170-25-053945
0000950170-25-053945 20241231 Liabilities 16388000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Long Term Debt Noncurrent 124000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Loss On Disposal Of Property And Equipment 2000.0000 USD 4 0000950170-25-053945
0000950170-25-053945 20231231 Net Cash Provided By Used In Operating Activities -33275000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Other Liabilities Noncurrent 236000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0000950170-25-053945 20231231 Proceeds From Warrant Exercises 8000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Research And Development Expense 46418000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Right Of Use Asset Obtained In Exchange For Operating Lease Liability 11000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Stockholders Equity -250268000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-053945 20241231 Stock Issued During Period Value Employee Stock Purchase Plan 66000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Stock Issued During Period Value Of Common Stock And Warrants 50894000.0000 USD 4 0000950170-25-053945 Equity Components= Additional Paid In Capital;
0000950170-25-053945 20241231 Weighted Average Number Of Diluted Shares Outstanding 41264948.0000 shares 4 us-gaap/2024
0000950170-25-053945 20241231 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 5348000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Accretion Amortization Of Discounts And Premiums Investments 0.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Accrued Expenses And Other Current Liabilities 12329000.0000 USD 0 0000950170-25-053945
0000950170-25-053945 20241231 Accrued Expenses And Other Current Liabilities 500000.0000 USD 0 0000950170-25-053945 Type Of Arrangement= Twist License Agreement;
0000950170-25-053945 20231231 Commitments And Contingencies USD 0 us-gaap/2024
0000950170-25-053945 20231231 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Deferred Offering Costs Included In Accrued Expenses 51000.0000 USD 4 0000950170-25-053945
0000950170-25-053945 20231231 Deferred Revenue Current 4911000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Depreciation And Amortization 46000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Earnings Per Share Basic -1.2900 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Exercise Of Pre Funded Warrants 8000.0000 USD 4 0000950170-25-053945
0000950170-25-053945 20231231 Increase Decrease In Other Operating Liabilities -176000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Interest And Other Income 4557000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Net Cash Provided By Used In Financing Activities -1622000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Operating Income Loss -51993000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Operating Lease Liability Noncurrent 736000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 0.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Payments To Acquire Property Plant And Equipment 0.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Preferred Stock Shares Authorized 10000000.0000 shares 0 us-gaap/2024
0000950170-25-053945 20241231 Preferred Stock Shares Authorized 10000000.0000 shares 0 us-gaap/2024
0000950170-25-053945 20241231 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0000950170-25-053945 20241231 Repayments Of Long Term Debt 1622000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Share Based Compensation 4622000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20221231 Stockholders Equity 68486000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20221231 Stockholders Equity 218354000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-053945 20231231 Stock Issued During Period Shares Stock Options Exercised 54.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-053945 20231231 Stock Issued During Period Value Employee Stock Purchase Plan 169000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-053945 20231231 Weighted Average Number Of Shares Outstanding Basic 38510220.0000 shares 4 us-gaap/2024
0000950170-25-053945 20241231 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 5348000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-053945 20231231 Assets Current 102183000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Common Stock Shares Outstanding 41029832.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-053945 20241231 Common Stock Shares Outstanding 42231285.0000 shares 0 us-gaap/2024
0000950170-25-053945 20231231 Exercise Of Pre Funded Warrants Shares 800000.0000 shares 4 0000950170-25-053945 Equity Components= Common Stock;
0000950170-25-053945 20241231 Increase Decrease In Accounts Payable -2037000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Increase Decrease In Accrued Liabilities -2271000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Increase Decrease In Deferred Revenue 4911000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Interest And Other Income 3422000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Interest Expense 483000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Lease Right Of Use Asset 934000.0000 USD 0 0000950170-25-053945
0000950170-25-053945 20231231 Liabilities And Stockholders Equity 103946000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Liabilities Current 24465000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Proceeds From Sale Maturity And Collections Of Investments 0.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Proceeds From Stock Plans 169000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Restricted Cash Noncurrent 35000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Retained Earnings Accumulated Deficit -250268000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Stockholders Equity 28821000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Stock Issued During Period Value Stock Options Exercised 1000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Stock Issued During Period Value Stock Options Exercised 1000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-053945 20231231 Weighted Average Number Of Diluted Shares Outstanding 38510220.0000 shares 4 us-gaap/2024
0000950170-25-053945 20231231 Accretion Amortization Of Discounts And Premiums Investments 636000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 4622000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 38788000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Common Stock And Warrant Net Offering Costs 2721000.0000 USD 4 0000950170-25-053945
0000950170-25-053945 20241231 Common Stock Shares Issued 42231285.0000 shares 0 us-gaap/2024
0000950170-25-053945 20221231 Common Stock Shares Outstanding 23601004.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-053945 20241231 Common Stock Shares Outstanding 42231285.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-053945 20241231 Common Stock Value 4000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Comprehensive Income Net Of Tax -53036000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Earnings Per Share Diluted -1.2900 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Increase Decrease In Other Operating Liabilities -237000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Loss On Disposal Of Property And Equipment 2000.0000 USD 4 0000950170-25-053945
0000950170-25-053945 20231231 Net Cash Provided By Used In Investing Activities 55777000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Net Income Loss -47919000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Other Assets Noncurrent 582000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Proceeds From Issuance Of Common Stock And Warrants 53616000.0000 USD 4 0000950170-25-053945
0000950170-25-053945 20241231 Proceeds From Issuance Of Common Stock And Warrants 0.0000 USD 4 0000950170-25-053945
0000950170-25-053945 20241231 Proceeds From Stock Options Exercised 180000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Profit Loss -47919000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Restricted Cash Noncurrent 35000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Stock Issued During Period Shares Employee Stock Purchase Plans 162791.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-053945 20231231 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 4622000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-053945 20231231 Cash And Cash Equivalents At Carrying Value 96339000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Comprehensive Income Net Of Tax -47361000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Earnings Per Share Diluted -1.2400 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Liabilities Current 15246000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Long Term Debt Current 1622000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Long Term Debt Current 1622000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Net Cash Provided By Used In Investing Activities 0.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Net Income Loss -53036000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Non Cash Lease Expense 247000.0000 USD 4 0000950170-25-053945
0000950170-25-053945 20231231 Operating Expenses 62082000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Operating Income Loss -56151000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Other Assets Noncurrent 69000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20231231 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 558000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Payments Of Stock Issuance Costs 0.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Payments Related To Tax Withholding For Share Based Compensation 246000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Payments To Acquire Investments 11881000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Prepaid Expense Current 3876000.0000 USD 0 us-gaap/2024
0000950170-25-053945 20241231 Proceeds From Stock Plans 66000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Proceeds From Warrant Exercises 0.0000 USD 4 us-gaap/2024
0000950170-25-053945 20231231 Research And Development Expense 49432000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Restricted Stock Shares Issued Net Of Shares For Tax Withholdings 922556.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-053945 20221231 Stockholders Equity -149313000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-053945 20241231 Stock Issued During Period Value Stock Options Exercised 180000.0000 USD 4 us-gaap/2024
0000950170-25-053945 20241231 Stock Issued During Period Value Stock Options Exercised 180000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-064463 20241231 Accounts Payable Current 1295000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 544000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-064463 20241231 Assets 45209000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20240331 Cash And Cash Equivalents At Carrying Value 81154000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 38788000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20241231 Commitments And Contingencies USD 0 us-gaap/2024
0000950170-25-064463 20241231 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0000950170-25-064463 20241231 Common Stock Shares Outstanding 42231285.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-064463 20240331 Earnings Per Share Basic -0.2800 USD 1 us-gaap/2024
0000950170-25-064463 20240331 General And Administrative Expense 4318000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Increase Decrease In Other Operating Assets 0.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Non Cash Lease Expense 60000.0000 USD 1 0000950170-25-064463
0000950170-25-064463 20250331 Payments Of Stock Issuance Costs 6000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Repayments Of Long Term Debt 405000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20231231 Stockholders Equity 273737000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-064463 20240331 Stockholders Equity -208857000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-064463 20250331 Stockholders Equity 4000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-064463 20240331 Weighted Average Number Of Shares Outstanding Basic 41096231.0000 shares 1 us-gaap/2024
0000950170-25-064463 20250331 Net Cash Provided By Used In Financing Activities -411000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Operating Expenses 14492000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Common Stock Shares Outstanding 41154799.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-064463 20241231 Other Assets Current 2276000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20241231 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0000950170-25-064463 20240331 Depreciation And Amortization 15000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Interest Expense 97000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Liabilities And Stockholders Equity 31649000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20241231 Accrued Expenses And Other Current Liabilities 12329000.0000 USD 0 0000950170-25-064463
0000950170-25-064463 20241231 Additional Paid In Capital Common Stock 279085000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 544000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20241231 Assets Current 44206000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20241231 Cash And Cash Equivalents At Carrying Value 38753000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Cash And Cash Equivalents At Carrying Value 25615000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Common Stock Shares Authorized 200000000.0000 shares 0 us-gaap/2024
0000950170-25-064463 20240331 Net Cash Provided By Used In Financing Activities -227000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20241231 Prepaid Expense Current 3177000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20240331 Stockholders Equity 275477000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-064463 20241231 Stockholders Equity 4000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-064463 20250331 Stockholders Equity -264309000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-064463 20250331 Accounts Payable Current 1879000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Additional Paid In Capital Common Stock 279629000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Assets 31649000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 81189000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Depreciation And Amortization 6000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Fair Value Adjustment Of Warrants -158000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Increase Decrease In Other Operating Assets -74000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Increase Decrease In Other Operating Liabilities -359000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Increase Decrease In Prepaid Deferred Expense And Other Assets 191000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Interest And Other Income 1105000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20241231 Liabilities 16388000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Liabilities Current 15666000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20240331 Net Income Loss -11625000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Net Income Loss -14041000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Other Assets Current 2062000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Other Liabilities Noncurrent 0.0000 USD 0 us-gaap/2024
0000950170-25-064463 20240331 Payments Related To Tax Withholding For Share Based Compensation 2000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0000950170-25-064463 20250331 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0000950170-25-064463 20240331 Restricted Cash Noncurrent 35000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20231231 Stockholders Equity 4000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-064463 20240331 Stockholders Equity 66624000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20241231 Stockholders Equity -250268000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-064463 20240331 Weighted Average Number Of Diluted Shares Outstanding 41096231.0000 shares 1 us-gaap/2024
0000950170-25-064463 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 1562000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 1562000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-064463 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect -13138000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Common Stock Shares Issued 42231285.0000 shares 0 us-gaap/2024
0000950170-25-064463 20240331 Net Income Loss -11625000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-064463 20250331 Net Income Loss -14041000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0000950170-25-064463 20241231 Operating Lease Liability Noncurrent 736000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Operating Lease Liability Noncurrent 659000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20241231 Preferred Stock Shares Authorized 10000000.0000 shares 0 us-gaap/2024
0000950170-25-064463 20241231 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0000950170-25-064463 20250331 Prepaid Expense Current 2899000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Profit Loss -14041000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Restricted Stock Value Shares Issued Net Of Tax Withholdings -2000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-064463 20250331 Weighted Average Number Of Diluted Shares Outstanding 43944946.0000 shares 1 us-gaap/2024
0000950170-25-064463 20250331 Assets Current 30576000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 96374000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Commitments And Contingencies USD 0 us-gaap/2024
0000950170-25-064463 20250331 Earnings Per Share Diluted -0.3200 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Fair Value Adjustment Of Warrants 0.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Increase Decrease In Accounts Payable 584000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Increase Decrease In Accrued Liabilities 140000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Increase Decrease In Deferred Revenue 0.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Increase Decrease In Other Operating Liabilities -55000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Interest And Other Income 487000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Interest Expense 36000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20241231 Liabilities Current 15246000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Preferred Stock Shares Authorized 10000000.0000 shares 0 us-gaap/2024
0000950170-25-064463 20241231 Long Term Debt Current 1622000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20240331 Operating Expenses 14635000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20241231 Other Assets Noncurrent 69000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20240331 Payments Of Stock Issuance Costs 0.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Payments Related To Tax Withholding For Share Based Compensation 0.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Share Based Compensation 544000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Stock Issued During Period Value Stock Options Exercised 180000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Preferred Stock Value 0.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Accrued Expenses And Other Current Liabilities 12442000.0000 USD 0 0000950170-25-064463
0000950170-25-064463 20231231 Common Stock Shares Outstanding 41029832.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-064463 20241231 Common Stock Shares Outstanding 42231285.0000 shares 0 us-gaap/2024
0000950170-25-064463 20250331 Common Stock Shares Outstanding 42231285.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000950170-25-064463 20250331 Common Stock Value 4000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Other Assets Noncurrent 204000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20240331 Proceeds From Stock Options Exercised 180000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Profit Loss -11625000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Restricted Cash Noncurrent 35000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20241231 Retained Earnings Accumulated Deficit -250268000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20240331 Revenues 2002000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20241231 Stockholders Equity 28821000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Stockholders Equity 15324000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20240331 Stock Issued During Period Value Stock Options Exercised 180000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000950170-25-064463 20250331 Increase Decrease In Prepaid Deferred Expense And Other Assets -492000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Common Stock Shares Outstanding 42231285.0000 shares 0 us-gaap/2024
0000950170-25-064463 20241231 Common Stock Value 4000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Earnings Per Share Basic -0.3200 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Earnings Per Share Diluted -0.2800 USD 1 us-gaap/2024
0000950170-25-064463 20250331 General And Administrative Expense 3655000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Increase Decrease In Accounts Payable -1441000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Increase Decrease In Accrued Liabilities -1354000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Increase Decrease In Deferred Revenue -2003000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20241231 Lease Right Of Use Asset 934000.0000 USD 0 0000950170-25-064463
0000950170-25-064463 20250331 Lease Right Of Use Asset 869000.0000 USD 0 0000950170-25-064463
0000950170-25-064463 20250331 Liabilities 16325000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Long Term Debt Current 1345000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20240331 Net Cash Provided By Used In Operating Activities -14958000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Operating Income Loss -12633000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Operating Income Loss -14492000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20241231 Other Liabilities Noncurrent 282000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20241231 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0000950170-25-064463 20241231 Preferred Stock Value 0.0000 USD 0 us-gaap/2024
0000950170-25-064463 20240331 Research And Development Expense 10317000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Research And Development Expense 10837000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20240331 Restricted Stock Value Shares Issued Net Of Tax Withholdings -2000.0000 USD 1 us-gaap/2024
0000950170-25-064463 20250331 Retained Earnings Accumulated Deficit -264309000.0000 USD 0 us-gaap/2024
0000950170-25-064463 20250331 Revenues 0.0000 USD 1 us-gaap/2024

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Stock Issued During Period Value Stock Options Exercised us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Stock Options Exercised Value of stock issued as a result of the exercise of stock options.
Non Cash Lease Expense 0000950170-25-053945 1 0 monetary D D Non Cash Lease Expense Amount of amortization expense for right-of-use asset from leases.
Assets Current us-gaap/2024 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Depreciation And Amortization us-gaap/2024 0 0 monetary D D Depreciation, Depletion and Amortization, Nonproduction The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
Payments To Acquire Property Plant And Equipment us-gaap/2024 0 0 monetary D C Payments to Acquire Property, Plant, and Equipment The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Right Of Use Asset Obtained In Exchange For Operating Lease Liability us-gaap/2024 0 0 monetary D D Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Amount of increase in right-of-use asset obtained in exchange for operating lease liability.
Comprehensive Income Net Of Tax us-gaap/2024 0 0 monetary D C Comprehensive Income (Loss), Net of Tax, Attributable to Parent Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Deferred Revenue Current us-gaap/2024 0 0 monetary I C Deferred Revenue, Current Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.
Liabilities us-gaap/2024 0 0 monetary I C Liabilities Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
Liabilities And Stockholders Equity us-gaap/2024 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax us-gaap/2024 0 0 monetary D C OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.
Proceeds From Stock Options Exercised us-gaap/2024 0 0 monetary D D Proceeds from Stock Options Exercised Amount of cash inflow from exercise of option under share-based payment arrangement.
Retained Earnings Accumulated Deficit us-gaap/2024 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Lease Right Of Use Asset 0000950170-25-053945 1 0 monetary I D Lease Right of Use Asset Amount of lessee's right to use underlying asset under leases.
Stock Issued During Period Value Of Common Stock And Warrants 0000950170-25-053945 1 0 monetary D C Stock Issued During Period Value Of Common Stock And Warrants Value of common stock and warrants issued.
Common Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Common Stock, Par or Stated Value Per Share Face amount or stated value per share of common stock.
Accrued Expenses And Other Current Liabilities 0000950170-25-064463 1 0 monetary I C Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities.
Non Cash Lease Expense 0000950170-25-064463 1 0 monetary D D Amount of Amortization Expense for Right-Of-Use Asset From Leases Amount of amortization expense for right-of-use asset from leases.
Common Stock Shares Outstanding us-gaap/2024 0 0 shares I Common Stock, Shares, Outstanding Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Net Income Loss us-gaap/2024 0 0 monetary D C Net Income (Loss) Attributable to Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Payments To Acquire Investments us-gaap/2024 0 0 monetary D C Payments to Acquire Investments The cash outflow associated with the purchase of all investments (debt, security, other) during the period.
Prepaid Expense Current us-gaap/2024 0 0 monetary I D Prepaid Expense, Current Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
Stockholders Equity us-gaap/2024 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Stock Issued During Period Value Employee Stock Purchase Plan us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Employee Stock Purchase Plan Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.
Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Diluted The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Assets us-gaap/2024 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Common Stock Shares Issued us-gaap/2024 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Earnings Per Share Diluted us-gaap/2024 0 0 perShare D Earnings Per Share, Diluted The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Interest Expense us-gaap/2024 0 0 monetary D D Interest Expense, Operating and Nonoperating Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.
Other Assets Noncurrent us-gaap/2024 0 0 monetary I D Other Assets, Noncurrent Amount of noncurrent assets classified as other.
Proceeds From Issuance Of Common Stock And Warrants 0000950170-25-053945 1 0 monetary D D Proceeds from Issuance of Common Stock and Warrants The cash inflow from the issuance of common stock and warrants.
Increase Decrease In Other Operating Assets us-gaap/2024 0 0 monetary D C Increase (Decrease) in Other Operating Assets Amount of increase (decrease) in operating assets classified as other.
Liabilities Current us-gaap/2024 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Preferred Stock Shares Issued us-gaap/2024 0 0 shares I Preferred Stock, Shares Issued Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.
Repayments Of Long Term Debt us-gaap/2024 0 0 monetary D C Repayments of Long-Term Debt The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.
Share Based Compensation us-gaap/2024 0 0 monetary D D Share-Based Payment Arrangement, Noncash Expense Amount of noncash expense for share-based payment arrangement.
Lease Right Of Use Asset 0000950170-25-064463 1 0 monetary I D Lease Right of Use Asset Amount of lessee's right to use underlying asset under leases.
Loss On Disposal Of Property And Equipment 0000950170-25-053945 1 0 monetary D D Loss on Disposal of Property and Equipment Loss on disposal of property and equipment
Common Stock And Warrant Net Offering Costs 0000950170-25-053945 1 0 monetary D D Common Stock and Warrant Net Offering Costs Common stock and warrant net offering costs.
Cash And Cash Equivalents At Carrying Value us-gaap/2024 0 0 monetary I D Cash and Cash Equivalents, at Carrying Value Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Increase Decrease In Other Operating Liabilities us-gaap/2024 0 0 monetary D D Increase (Decrease) in Other Operating Liabilities Amount of increase (decrease) in operating liabilities classified as other.
Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 0 0 monetary D C Increase (Decrease) in Prepaid Expense and Other Assets Amount of increase (decrease) in prepaid expenses, and assets classified as other.
Payments Of Stock Issuance Costs us-gaap/2024 0 0 monetary D C Payments of Stock Issuance Costs The cash outflow for cost incurred directly with the issuance of an equity security.
Preferred Stock Value us-gaap/2024 0 0 monetary I C Preferred Stock, Value, Issued Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
Profit Loss us-gaap/2024 0 0 monetary D C Net Income (Loss), Including Portion Attributable to Noncontrolling Interest The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
Interest And Other Income us-gaap/2024 0 0 monetary D C Interest and Other Income The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).
Net Cash Provided By Used In Operating Activities us-gaap/2024 0 0 monetary D Net Cash Provided by (Used in) Operating Activities Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Other Liabilities Noncurrent us-gaap/2024 0 0 monetary I C Other Liabilities, Noncurrent Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
Operating Expenses us-gaap/2024 0 0 monetary D D Operating Expenses Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
Operating Income Loss us-gaap/2024 0 0 monetary D C Operating Income (Loss) The net result for the period of deducting operating expenses from operating revenues.
Other Assets Current us-gaap/2024 0 0 monetary I D Other Assets, Current Amount of current assets classified as other.
Restricted Cash Noncurrent us-gaap/2024 0 0 monetary I D Restricted Cash, Noncurrent Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
Restricted Stock Value Shares Issued Net Of Tax Withholdings us-gaap/2024 0 0 monetary D C Restricted Stock, Value, Shares Issued Net of Tax Withholdings Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Common Stock Value us-gaap/2024 0 0 monetary I C Common Stock, Value, Issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
General And Administrative Expense us-gaap/2024 0 0 monetary D D General and Administrative Expense The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Accounts Payable Current us-gaap/2024 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Proceeds From Stock Plans us-gaap/2024 0 0 monetary D D Proceeds from Stock Plans The cash inflow associated with the amount received from the stock plan during the period.
Research And Development Expense us-gaap/2024 0 0 monetary D D Research and Development Expense Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
Revenues us-gaap/2024 0 0 monetary D C Revenues Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Deferred Offering Costs Included In Accrued Expenses 0000950170-25-053945 1 0 monetary D D Deferred Offering Costs Included In Accrued Expenses Deferred offering costs included in accrued expenses.
Stock Issued During Period Shares Of Common Stock And Warrants 0000950170-25-053945 1 0 shares D Stock Issued During Period Shares Of Common Stock And Warrants Number of shares Issued for common stock and warrants.
Additional Paid In Capital Common Stock us-gaap/2024 0 0 monetary I C Additional Paid in Capital, Common Stock Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
Commitments And Contingencies us-gaap/2024 0 0 monetary I C Commitments and Contingencies Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Common Stock Shares Authorized us-gaap/2024 0 0 shares I Common Stock, Shares Authorized The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Fair Value Adjustment Of Warrants us-gaap/2024 0 0 monetary D D Fair Value Adjustment of Warrants Amount of expense (income) related to adjustment to fair value of warrant liability.
Payments Related To Tax Withholding For Share Based Compensation us-gaap/2024 0 0 monetary D C Payment, Tax Withholding, Share-Based Payment Arrangement Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.
Increase Decrease In Accounts Payable us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accounts Payable The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
Interest Paid Net us-gaap/2024 0 0 monetary D C Interest Paid, Excluding Capitalized Interest, Operating Activities Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
Net Cash Provided By Used In Financing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Financing Activities Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Preferred Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Preferred Stock, Par or Stated Value Per Share Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
Accrued Expenses And Other Current Liabilities 0000950170-25-053945 1 0 monetary I C Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities.
Restricted Stock Shares Issued Net Of Shares For Tax Withholdings us-gaap/2024 0 0 shares D Restricted Stock, Shares Issued Net of Shares for Tax Withholdings Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.
Exercise Of Pre Funded Warrants 0000950170-25-053945 1 0 monetary D C Exercise of Pre-funded Warrants Value of pre-funded warrants exercised.
Exercise Of Pre Funded Warrants Shares 0000950170-25-053945 1 0 shares D Exercise of Pre-funded Warrants, Shares Number of pre-funded warrants exercised.
Accretion Amortization Of Discounts And Premiums Investments us-gaap/2024 0 0 monetary D C Accretion (Amortization) of Discounts and Premiums, Investments The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2024 0 0 monetary D C APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
Earnings Per Share Basic us-gaap/2024 0 0 perShare D Earnings Per Share, Basic The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Net Cash Provided By Used In Investing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Investing Activities Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Preferred Stock Shares Authorized us-gaap/2024 0 0 shares I Preferred Stock, Shares Authorized The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
Preferred Stock Shares Outstanding us-gaap/2024 0 0 shares I Preferred Stock, Shares Outstanding Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
Stock Issued During Period Shares Employee Stock Purchase Plans us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Employee Stock Purchase Plans Number of shares issued during the period as a result of an employee stock purchase plan.
Stock Issued During Period Shares Stock Options Exercised us-gaap/2024 0 0 shares D Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Number of share options (or share units) exercised during the current period.
Increase Decrease In Accrued Liabilities us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accrued Liabilities The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
Increase Decrease In Deferred Revenue us-gaap/2024 0 0 monetary D D Increase (Decrease) in Deferred Revenue Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.
Long Term Debt Current us-gaap/2024 0 0 monetary I C Long-Term Debt, Current Maturities Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.
Long Term Debt Noncurrent us-gaap/2024 0 0 monetary I C Long-Term Debt, Excluding Current Maturities Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.
Operating Lease Liability Noncurrent us-gaap/2024 0 0 monetary I C Operating Lease, Liability, Noncurrent Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
Proceeds From Sale Maturity And Collections Of Investments us-gaap/2024 0 0 monetary D D Proceeds from Sale, Maturity and Collection of Investments The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.
Proceeds From Warrant Exercises us-gaap/2024 0 0 monetary D D Proceeds from Warrant Exercises The cash inflow associated with the amount received from holders exercising their stock warrants.
Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Basic Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0000950170-25-053945 2 5 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0000950170-25-053945 2 6 BS 0 H Prepaid Expense Current us-gaap/2024 Prepaid expenses 0
0000950170-25-053945 2 7 BS 0 H Other Assets Current us-gaap/2024 Other current assets 0
0000950170-25-053945 2 8 BS 0 H Assets Current us-gaap/2024 Total current assets 0
0000950170-25-053945 2 9 BS 0 H Lease Right Of Use Asset 0000950170-25-053945 Right-of-use assets 0
0000950170-25-053945 2 10 BS 0 H Other Assets Noncurrent us-gaap/2024 Other assets 0
0000950170-25-053945 2 11 BS 0 H Assets us-gaap/2024 Total assets 0
0000950170-25-053945 2 14 BS 0 H Accounts Payable Current us-gaap/2024 Accounts payable 0
0000950170-25-053945 2 15 BS 0 H Accrued Expenses And Other Current Liabilities 0000950170-25-053945 Accrued expenses and other current liabilities 0
0000950170-25-053945 2 16 BS 0 H Long Term Debt Current us-gaap/2024 Term loan, current portion 0
0000950170-25-053945 2 17 BS 0 H Deferred Revenue Current us-gaap/2024 Deferred revenue 0
0000950170-25-053945 2 18 BS 0 H Liabilities Current us-gaap/2024 Total current liabilities 0
0000950170-25-053945 2 19 BS 0 H Operating Lease Liability Noncurrent us-gaap/2024 Lease liabilities, net of current portion 0
0000950170-25-053945 2 20 BS 0 H Long Term Debt Noncurrent us-gaap/2024 Term loan, net of current portion 0
0000950170-25-053945 2 21 BS 0 H Other Liabilities Noncurrent us-gaap/2024 Other liabilities 0
0000950170-25-053945 2 22 BS 0 H Liabilities us-gaap/2024 Total liabilities 0
0000950170-25-053945 2 23 BS 0 H Commitments And Contingencies us-gaap/2024 Commitments and contingencies (Note 7) 0
0000950170-25-053945 2 25 BS 0 H Preferred Stock Value us-gaap/2024 Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2024 and 2023 0
0000950170-25-053945 2 26 BS 0 H Common Stock Value us-gaap/2024 Common stock, $0.0001 par value; 200,000,000 shares authorized as of December 31, 2024 and 2023; 42,231,285 and 41,029,832 shares issued and outstanding as of December 31, 2024 and 2023, respectively 0
0000950170-25-053945 2 27 BS 0 H Additional Paid In Capital Common Stock us-gaap/2024 Additional paid-in capital 0
0000950170-25-053945 2 28 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Accumulated deficit 0
0000950170-25-053945 2 29 BS 0 H Stockholders Equity us-gaap/2024 Total stockholders' equity 0
0000950170-25-053945 2 30 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 Total liabilities and stockholders' equity 0
0000950170-25-053945 3 3 BS 1 H Preferred Stock Par Or Stated Value Per Share us-gaap/2024 Preferred Stock, Par Value 0
0000950170-25-053945 3 4 BS 1 H Preferred Stock Shares Authorized us-gaap/2024 Preferred stock, shares authorized 0
0000950170-25-053945 3 5 BS 1 H Preferred Stock Shares Issued us-gaap/2024 Preferred stock, shares issued 0
0000950170-25-053945 3 6 BS 1 H Preferred Stock Shares Outstanding us-gaap/2024 Preferred stock, shares outstanding 0
0000950170-25-053945 3 7 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Common stock, par value 0
0000950170-25-053945 3 8 BS 1 H Common Stock Shares Authorized us-gaap/2024 Common stock, shares authorized 0
0000950170-25-053945 3 9 BS 1 H Common Stock Shares Issued us-gaap/2024 Common stock, shares sold and issued 0
0000950170-25-053945 3 10 BS 1 H Common Stock Shares Outstanding us-gaap/2024 Common stock, shares outstanding 0
0000950170-25-053945 4 1 IS 0 H Revenues us-gaap/2024 Collaboration revenue 0
0000950170-25-053945 4 3 IS 0 H Research And Development Expense us-gaap/2024 Research and development 0
0000950170-25-053945 4 4 IS 0 H General And Administrative Expense us-gaap/2024 General and administrative 0
0000950170-25-053945 4 5 IS 0 H Operating Expenses us-gaap/2024 Total operating expenses 0
0000950170-25-053945 4 6 IS 0 H Operating Income Loss us-gaap/2024 Loss from operations 0
0000950170-25-053945 4 7 IS 0 H Interest Expense us-gaap/2024 Interest expense 1
0000950170-25-053945 4 8 IS 0 H Interest And Other Income us-gaap/2024 Interest and other income, net 0
0000950170-25-053945 4 9 IS 0 H Net Income Loss us-gaap/2024 Net loss 0
0000950170-25-053945 4 11 IS 0 H Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax us-gaap/2024 Unrealized gain on available for sale securities 0
0000950170-25-053945 4 12 IS 0 H Comprehensive Income Net Of Tax us-gaap/2024 Total comprehensive loss 0
0000950170-25-053945 4 13 IS 0 H Earnings Per Share Basic us-gaap/2024 Net loss per share, basic 0
0000950170-25-053945 4 14 IS 0 H Earnings Per Share Diluted us-gaap/2024 Net loss per share,diluted 0
0000950170-25-053945 4 15 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 Weighted-average shares of common stock outstanding, basic 0
0000950170-25-053945 4 16 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 Weighted-average shares of common stock outstanding,diluted 0
0000950170-25-053945 5 9 EQ 0 H Stockholders Equity us-gaap/2024 Balance 0
0000950170-25-053945 5 10 EQ 0 H Common Stock Shares Outstanding us-gaap/2024 Balance, Shares 0
0000950170-25-053945 5 11 EQ 0 H Stock Issued During Period Value Stock Options Exercised us-gaap/2024 Exercise of common stock options 0
0000950170-25-053945 5 12 EQ 0 H Stock Issued During Period Shares Stock Options Exercised us-gaap/2024 Exercise of common stock options, Shares 0
0000950170-25-053945 5 13 EQ 0 H Exercise Of Pre Funded Warrants 0000950170-25-053945 Exercise of pre-funded warrants 0
0000950170-25-053945 5 14 EQ 0 H Exercise Of Pre Funded Warrants Shares 0000950170-25-053945 Exercise of pre-funded warrants, Shares 0
0000950170-25-053945 5 15 EQ 0 H Stock Issued During Period Value Employee Stock Purchase Plan us-gaap/2024 Issuance of common stock related to employee stock purchase plan 0
0000950170-25-053945 5 16 EQ 0 H Stock Issued During Period Shares Employee Stock Purchase Plans us-gaap/2024 Issuance of common stock related to employee stock purchase plan,shares 0
0000950170-25-053945 5 17 EQ 0 H Restricted Stock Value Shares Issued Net Of Tax Withholdings us-gaap/2024 Issuance of common stock related to vesting of restricted stock units, net of tax withholdings 0
0000950170-25-053945 5 18 EQ 0 H Restricted Stock Shares Issued Net Of Shares For Tax Withholdings us-gaap/2024 Issuance of common stock related to vesting of restricted stock units, net of tax withholdings,shares 0
0000950170-25-053945 5 19 EQ 0 H Stock Issued During Period Shares Of Common Stock And Warrants 0000950170-25-053945 Issuance of common stock and warrants, net of offering costs, shares 0
0000950170-25-053945 5 20 EQ 0 H Stock Issued During Period Value Of Common Stock And Warrants 0000950170-25-053945 Issuance of common stock and warrants, net of offering costs 0
0000950170-25-053945 5 21 EQ 0 H Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2024 Stock-based compensation 0
0000950170-25-053945 5 22 EQ 0 H Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax us-gaap/2024 Unrealized loss on available for sale securities 0
0000950170-25-053945 5 23 EQ 0 H Net Income Loss us-gaap/2024 Net loss 0
0000950170-25-053945 5 24 EQ 0 H Stockholders Equity us-gaap/2024 Balance 0
0000950170-25-053945 5 25 EQ 0 H Common Stock Shares Outstanding us-gaap/2024 Balance, Shares 0
0000950170-25-053945 6 1 EQ 1 H Common Stock And Warrant Net Offering Costs 0000950170-25-053945 Offering costs 0
0000950170-25-053945 7 4 CF 0 H Profit Loss us-gaap/2024 Net loss 0
0000950170-25-053945 7 6 CF 0 H Share Based Compensation us-gaap/2024 Stock-based compensation expense 0
0000950170-25-053945 7 7 CF 0 H Depreciation And Amortization us-gaap/2024 Depreciation and amortization 0
0000950170-25-053945 7 8 CF 0 H Accretion Amortization Of Discounts And Premiums Investments us-gaap/2024 Net accretion of discount on available-for-sale securities 1
0000950170-25-053945 7 9 CF 0 H Non Cash Lease Expense 0000950170-25-053945 Non-cash lease expense 0
0000950170-25-053945 7 10 CF 0 H Loss On Disposal Of Property And Equipment 0000950170-25-053945 Loss on disposal of property and equipment 0
0000950170-25-053945 7 12 CF 0 H Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 Prepaid expenses and other current assets 1
0000950170-25-053945 7 13 CF 0 H Increase Decrease In Other Operating Assets us-gaap/2024 Other assets 1
0000950170-25-053945 7 14 CF 0 H Increase Decrease In Accounts Payable us-gaap/2024 Accounts payable 0
0000950170-25-053945 7 15 CF 0 H Increase Decrease In Accrued Liabilities us-gaap/2024 Accrued expenses and other current liabilities 0
0000950170-25-053945 7 16 CF 0 H Increase Decrease In Deferred Revenue us-gaap/2024 Deferred Revenue 0
0000950170-25-053945 7 17 CF 0 H Increase Decrease In Other Operating Liabilities us-gaap/2024 Other liabilities 0
0000950170-25-053945 7 18 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net cash used in operating activities 0
0000950170-25-053945 7 20 CF 0 H Proceeds From Sale Maturity And Collections Of Investments us-gaap/2024 Proceeds from maturities of investments 0
0000950170-25-053945 7 21 CF 0 H Payments To Acquire Investments us-gaap/2024 Purchases of investments 1
0000950170-25-053945 7 22 CF 0 H Payments To Acquire Property Plant And Equipment us-gaap/2024 Purchases of property and equipment 1
0000950170-25-053945 7 23 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2024 Net cash provided by investing activities 0
0000950170-25-053945 7 25 CF 0 H Proceeds From Issuance Of Common Stock And Warrants 0000950170-25-053945 Proceeds from Issuance of Common Stock and Warrants 0
0000950170-25-053945 7 26 CF 0 H Proceeds From Stock Plans us-gaap/2024 Proceeds from issuance of common stock related to employee stock purchase plan 0
0000950170-25-053945 7 27 CF 0 H Proceeds From Warrant Exercises us-gaap/2024 Proceeds from exercise of pre-funded warrants 0
0000950170-25-053945 7 28 CF 0 H Proceeds From Stock Options Exercised us-gaap/2024 Proceeds from exercise of common stock options 0
0000950170-25-053945 7 29 CF 0 H Payments Of Stock Issuance Costs us-gaap/2024 Payment of offering costs 1
0000950170-25-053945 7 30 CF 0 H Repayments Of Long Term Debt us-gaap/2024 Repayment of term loan 1
0000950170-25-053945 7 31 CF 0 H Payments Related To Tax Withholding For Share Based Compensation us-gaap/2024 Tax withholding payments on restricted stock units 1
0000950170-25-053945 7 32 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net cash provided by (used in) financing activities 0
0000950170-25-053945 7 33 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect us-gaap/2024 Net increase (decrease) in cash, cash equivalents, and restricted cash 0
0000950170-25-053945 7 34 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash, cash equivalents, and restricted cash at beginning of period 0
0000950170-25-053945 7 35 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash, cash equivalents, and restricted cash at end of period 0
0000950170-25-053945 7 37 CF 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0000950170-25-053945 7 38 CF 0 H Restricted Cash Noncurrent us-gaap/2024 Restricted cash, long-term (included in other assets) 0
0000950170-25-053945 7 39 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Total cash, cash equivalents and restricted cash 0
0000950170-25-053945 7 41 CF 0 H Interest Paid Net us-gaap/2024 Cash paid for interest on term loan 0
0000950170-25-053945 7 43 CF 0 H Deferred Offering Costs Included In Accrued Expenses 0000950170-25-053945 Deferred offering costs included in accrued expenses 0
0000950170-25-053945 7 44 CF 0 H Right Of Use Asset Obtained In Exchange For Operating Lease Liability us-gaap/2024 Right-of-use asset recognized in exchange for lease liability 0
0000950170-25-064463 2 3 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0000950170-25-064463 2 4 BS 0 H Prepaid Expense Current us-gaap/2024 Prepaid expenses 0
0000950170-25-064463 2 5 BS 0 H Other Assets Current us-gaap/2024 Other current assets 0
0000950170-25-064463 2 6 BS 0 H Assets Current us-gaap/2024 Total current assets 0
0000950170-25-064463 2 7 BS 0 H Lease Right Of Use Asset 0000950170-25-064463 Right-of-use assets 0
0000950170-25-064463 2 8 BS 0 H Other Assets Noncurrent us-gaap/2024 Other assets 0
0000950170-25-064463 2 9 BS 0 H Assets us-gaap/2024 Total assets 0
0000950170-25-064463 2 12 BS 0 H Accounts Payable Current us-gaap/2024 Accounts payable 0
0000950170-25-064463 2 13 BS 0 H Accrued Expenses And Other Current Liabilities 0000950170-25-064463 Accrued expenses and other current liabilities 0
0000950170-25-064463 2 14 BS 0 H Long Term Debt Current us-gaap/2024 Term loan, current portion 0
0000950170-25-064463 2 15 BS 0 H Liabilities Current us-gaap/2024 Total current liabilities 0
0000950170-25-064463 2 16 BS 0 H Operating Lease Liability Noncurrent us-gaap/2024 Lease liabilities, net of current portion 0
0000950170-25-064463 2 17 BS 0 H Long Term Debt Noncurrent us-gaap/2024 Term loan, current portion 0
0000950170-25-064463 2 18 BS 0 H Other Liabilities Noncurrent us-gaap/2024 Other liabilities 0
0000950170-25-064463 2 19 BS 0 H Liabilities us-gaap/2024 Total liabilities 0
0000950170-25-064463 2 20 BS 0 H Commitments And Contingencies us-gaap/2024 Commitments and contingencies 0
0000950170-25-064463 2 22 BS 0 H Preferred Stock Value us-gaap/2024 Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March 31, 2025 and December 31, 2024 0
0000950170-25-064463 2 23 BS 0 H Common Stock Value us-gaap/2024 Common stock, $0.0001 par value; 200,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 42,231,285 shares issued and outstanding as of March 31, 2025 and December 31, 2024 0
0000950170-25-064463 2 24 BS 0 H Additional Paid In Capital Common Stock us-gaap/2024 Additional paid-in capital 0
0000950170-25-064463 2 25 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Accumulated deficit 0
0000950170-25-064463 2 26 BS 0 H Stockholders Equity us-gaap/2024 Total stockholders' equity 0
0000950170-25-064463 2 27 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 Total liabilities and stockholders equity 0
0000950170-25-064463 3 1 BS 1 H Preferred Stock Par Or Stated Value Per Share us-gaap/2024 Preferred Stock, Par Value 0
0000950170-25-064463 3 2 BS 1 H Preferred Stock Shares Authorized us-gaap/2024 Preferred stock, shares authorized 0
0000950170-25-064463 3 3 BS 1 H Preferred Stock Shares Issued us-gaap/2024 Preferred stock, shares issued 0
0000950170-25-064463 3 4 BS 1 H Preferred Stock Shares Outstanding us-gaap/2024 Preferred stock, shares outstanding 0
0000950170-25-064463 3 5 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Common stock, par value 0
0000950170-25-064463 3 6 BS 1 H Common Stock Shares Authorized us-gaap/2024 Common stock, shares authorized 0
0000950170-25-064463 3 7 BS 1 H Common Stock Shares Issued us-gaap/2024 Common stock, shares issued 0
0000950170-25-064463 3 8 BS 1 H Common Stock Shares Outstanding us-gaap/2024 Common stock, shares outstanding 0
0000950170-25-064463 4 1 IS 0 H Revenues us-gaap/2024 Collaboration revenue 0
0000950170-25-064463 4 3 IS 0 H Research And Development Expense us-gaap/2024 Research and development 0
0000950170-25-064463 4 4 IS 0 H General And Administrative Expense us-gaap/2024 General and administrative 0
0000950170-25-064463 4 5 IS 0 H Operating Expenses us-gaap/2024 Total operating expenses 0
0000950170-25-064463 4 6 IS 0 H Operating Income Loss us-gaap/2024 Loss from operations 0
0000950170-25-064463 4 7 IS 0 H Interest Expense us-gaap/2024 Interest expense 1
0000950170-25-064463 4 8 IS 0 H Interest And Other Income us-gaap/2024 Interest and other income, net 0
0000950170-25-064463 4 9 IS 0 H Net Income Loss us-gaap/2024 Net loss and comprehensive loss 0
0000950170-25-064463 4 10 IS 0 H Earnings Per Share Basic us-gaap/2024 Net loss per share, basic 0
0000950170-25-064463 4 11 IS 0 H Earnings Per Share Diluted us-gaap/2024 Net loss per share, diluted 0
0000950170-25-064463 4 12 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 Weighted-average shares of common stock outstanding, basic 0
0000950170-25-064463 4 13 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 Weighted-average shares of common stock outstanding, diluted 0
0000950170-25-064463 5 8 EQ 0 H Stockholders Equity us-gaap/2024 Balance 0
0000950170-25-064463 5 9 EQ 0 H Common Stock Shares Outstanding us-gaap/2024 Balance, Shares 0
0000950170-25-064463 5 10 EQ 0 H Stock Issued During Period Value Stock Options Exercised us-gaap/2024 Exercise of common stock options 0
0000950170-25-064463 5 11 EQ 0 H Stock Issued During Period Shares Stock Options Exercised us-gaap/2024 Exercise of common stock options, Shares 0
0000950170-25-064463 5 12 EQ 0 H Restricted Stock Value Shares Issued Net Of Tax Withholdings us-gaap/2024 Issuance of common stock related to vesting of restricted stock units, net of tax withholdings 0
0000950170-25-064463 5 13 EQ 0 H Restricted Stock Shares Issued Net Of Shares For Tax Withholdings us-gaap/2024 Issuance of common stock related to vesting of restricted stock units, net of tax withholdings, shares 0
0000950170-25-064463 5 14 EQ 0 H Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2024 Stock-based compensation 0
0000950170-25-064463 5 15 EQ 0 H Net Income Loss us-gaap/2024 Net Income (Loss) 0
0000950170-25-064463 5 16 EQ 0 H Stockholders Equity us-gaap/2024 Balance 0
0000950170-25-064463 5 17 EQ 0 H Common Stock Shares Outstanding us-gaap/2024 Balance, Shares 0
0000950170-25-064463 6 2 CF 0 H Profit Loss us-gaap/2024 Net loss 0
0000950170-25-064463 6 4 CF 0 H Share Based Compensation us-gaap/2024 Stock-based compensation expense 0
0000950170-25-064463 6 5 CF 0 H Depreciation And Amortization us-gaap/2024 Depreciation and amortization 0
0000950170-25-064463 6 6 CF 0 H Non Cash Lease Expense 0000950170-25-064463 Non-cash lease expense 0
0000950170-25-064463 6 7 CF 0 H Fair Value Adjustment Of Warrants us-gaap/2024 Change in fair value of warrant liability 0
0000950170-25-064463 6 9 CF 0 H Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 Prepaid expenses and other current assets 1
0000950170-25-064463 6 10 CF 0 H Increase Decrease In Other Operating Assets us-gaap/2024 Other assets 1
0000950170-25-064463 6 11 CF 0 H Increase Decrease In Accounts Payable us-gaap/2024 Accounts payable 0
0000950170-25-064463 6 12 CF 0 H Increase Decrease In Accrued Liabilities us-gaap/2024 Accrued expenses and other current liabilities 0
0000950170-25-064463 6 13 CF 0 H Increase Decrease In Deferred Revenue us-gaap/2024 Deferred revenue 0
0000950170-25-064463 6 14 CF 0 H Increase Decrease In Other Operating Liabilities us-gaap/2024 Other liabilities 0
0000950170-25-064463 6 15 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net cash used in operating activities 0
0000950170-25-064463 6 17 CF 0 H Proceeds From Stock Options Exercised us-gaap/2024 Proceeds from exercise of common stock options 0
0000950170-25-064463 6 18 CF 0 H Repayments Of Long Term Debt us-gaap/2024 Repayment of term loan 1
0000950170-25-064463 6 19 CF 0 H Payments Of Stock Issuance Costs us-gaap/2024 Payment of offering costs 1
0000950170-25-064463 6 20 CF 0 H Payments Related To Tax Withholding For Share Based Compensation us-gaap/2024 Tax withholding payments on restricted stock units 1
0000950170-25-064463 6 21 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net cash used in financing activities 0
0000950170-25-064463 6 22 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect us-gaap/2024 Net decrease in cash, cash equivalents, and restricted cash 0
0000950170-25-064463 6 23 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash, cash equivalents, and restricted cash at beginning of period 0
0000950170-25-064463 6 24 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash, cash equivalents, and restricted cash at end of period 0
0000950170-25-064463 6 26 CF 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0000950170-25-064463 6 27 CF 0 H Restricted Cash Noncurrent us-gaap/2024 Restricted cash, long-term (included in other assets) 0
0000950170-25-064463 6 28 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Total cash, cash equivalents and restricted cash 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.